Log in to your Inderes Free account to see all free content on this page.

Modulight

0.94

EUR

+1.08 %

Corporate customer

MODU

First North Finland

Medical Equipment & Services

Health Care

2,688 following

+1.08%

-2.08%

-18.97%

-25.4%

-19.93%

-13.92%

-91.72%

-

-91.41%

Modulight operates in the technology industry. The company designs, markets, and produces biomedical laser products used in oncology, genetics, and ophthalmology. The customers primarily consist of hospitals and corporate customers operating in medical technology. In addition to the main business, various value-added services are also offered. Their main market is the US.

Market cap

40.06M EUR

Turnover

26.08K EUR

P/E (adj.) (24e)

EV/EBIT (adj.) (24e)

EV/S (24e)

Dividend yield-% (24e)

Coverage

Recommendation

Reduce

Target price

Updated

22.10.2024

Latest research

Latest analysis report

Released: 22.10.2024

Latest extensive report

Released: 21.03.2023

Risk

Business risk

Valuation risk

Low

High

ShowingAll content types

Analyst Commentyesterday by

Modulight receives order worth 0.5 MEUR

Delivery of the order is scheduled for the second half of 2025 and the first half of 2026.

Regulatory press release12/19/2024, 9:47 AM

Inside Information: Modulight Has Received an Order Worth EUR 0.5 Million

Regulatory press release12/19/2024, 8:02 AM

Modulight Corporation's Shareholders’ Nomination Committee Composition

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account

Stock market's most popular morning newsletter

Analyst comments and recommendations

Stock comparison tool

PREMIUM account

All company reports and content

Premium tools (e.g. insider transactions & stock screener)

Model portfolio

Drug development investment: Value creation through M&As and licensing agreements

Article12/19/2024, 11:07 AM by

Drug development investment: Value creation through M&As and licensing agreements

The fourth part of our series of articles focusing on investing in Life Science companies deals with value creation in drug development companies through M&As and licensing agreements.

Faron Pharmaceuticals Herantis Pharma Orion Modulight

Life Science Companies as Investments | Life Science Night Dec. 2, 2024

Video12/2/2024, 2:00 PM

Life Science Companies as Investments | Life Science Night Dec. 2, 2024

Antti Siltanen, Life Science Analyst, PhD, talks about life science companies as investments.

Aiforia Technologies BBS-Bioactive Bone Substitutes Bioretec Biohit Faron Pharmaceuticals Modulight Nexstim Orion Bittium Detection Technology Optomed Revenio Group Nightingale Health Herantis Pharma Nanoform Finland

Regulation of drug development

Analyst Comment12/3/2024, 10:21 AM by

Regulation of drug development

The third part in our series of articles on investing in Life Science companies deals with regulatory issues. Regulatory processes are demanding and time-consuming, and failure to comply can be disastrous for a drug development company.

Faron Pharmaceuticals Herantis Pharma Orion Mendus Modulight

Analyst Comment11/8/2024, 11:52 AM by

Pay-Per-Treatment model brings Modulight order intake

Modulight announced on Friday that it has secured contracts with a minimum cumulative value of EUR 1.5 MEUR over the next two years. The news adds further visibility to the progress of the revenue and PPT model in the coming years

Regulatory press release11/8/2024, 8:25 AM

Inside Information: Modulight has received PPT purchase orders worth of 1.5 million dollars

Research10/22/2024, 6:51 AM by

Modulight Q3'24: No clear signs of growth yet

Modulight's Q3 report showed no clear signs of a return to growth and revenue landed below expectations. Earnings and cash flow were roughly in line with our forecasts due to lower-than-expected costs.

Modulight Q3'24 flash comment: Revenue missed expectations - profit and cash flow close to forecasts

Analyst Comment10/18/2024, 12:41 PM by

Modulight Q3'24 flash comment: Revenue missed expectations - profit and cash flow close to forecasts

Modulight's revenue was well below our expectations, but profit and cash flow were close to our forecasts. Revenue was negatively impacted by the transition to the PPT (pay-per-treatment) model and delays in prototype deliveries.

Regulatory press release10/18/2024, 10:00 AM

Modulight: Cash flow development continued positive, progress with new business models

Modulight Q3'24 preview: Eye laser and clinical studies as revenue drivers

Analyst Comment10/16/2024, 6:22 AM by

Modulight Q3'24 preview: Eye laser and clinical studies as revenue drivers

Modulight will publish its Q3 results on Friday, October 18 at 1:00 pm EEST. We expect moderately growing revenue from Phase III clinical projects and ophthalmic lasers.

Press release10/14/2024, 10:00 AM

Modulight to publish its interim report for January–September 2024 on October 18, 2024

Regulatory press release9/16/2024, 10:20 AM

Modulight Corporation: Managers' Transactions – Jari Sillanpää

Regulatory press release9/16/2024, 10:20 AM

Modulight Corporation: Managers' Transactions – Virpi Sillanpää

Regulatory press release9/11/2024, 10:00 AM

Modulight Corporation: Managers' Transactions – Jari Hopsu

Regulatory press release9/11/2024, 10:00 AM

Modulight Corporation: Managers' Transactions – Ulla Haapanen

Regulatory press release8/22/2024, 12:30 PM

Modulight Corporation: Managers' Transactions – Lasse Orsila

Research8/19/2024, 8:51 AM by

Modulight Q2'24: Top line needs a boost

Modulight's Q2 revenue declined year-on-year and missed our forecasts. However, operating loss was lower than expected. The company had expanded its project pipeline to 30 and continued to roll out its pay-per-treatment (PPT) pricing model during the period. The model is not generating significant revenue at this time.

Regulatory press release8/16/2024, 10:02 AM

Modulight: Implementation of the new business model progressed and cash flow improved

Forum discussions

Tärkeimmät talousuutiset | Kauppalehti – 8 Nov 24 Sisäpiiritieto: Modulight on saanut PPT-tilauksia 1,5 miljoonan dollarin arvosta Tärkeimmät ajankohtaiset talousuutiset, pörssikurssit ja kattavat sijoittajapalvelut löydät Kauppalehdestä.

11/8/2024, 8:41 AM

by Mark_Renton

11

Modulight näyttäisi julkaisseen lupaavia tuloksia mesoteliooman hoidosta. Modulight Spotlights: LASER-SHARP RESEARCH - December 2024 – Modulight Corporation

12/18/2024, 7:21 PM

by Kalle Melanen

7

Käsittääkseni viranomaishyväksynnät on tarkoitus hakea valoaktivoitavan lääkkeen (lääkekehitysyhtiö) ja aktivoivan laser-laitteiston (Modulight) yhdistelmälle. Eli jompikumpi taho on varmaankin vastuullinen hakija ja toinen partnerin roolissa, mutta yhteinen hakemus jokatapauksessa...

12/17/2024, 12:41 PM

by Antti Siltanen

7

Tässä kommenttia aamun uutiseen vielä foorumin puolellekin: Inderes Modulightille tilauskertymää hoitokertakohtaisesta mallista - Inderes Modulight tiedotti perjantaina tehneensä sopimuksia, joiden vähimmäisarvo kumulatiivisesti on 1,5 MEUR seuraavan kahden vuoden aikana. Uutinen...

11/8/2024, 1:01 PM

by Antti Siltanen

7

Tässä Antin tiiviit kommentit Modulightin pikkutilauksesta. Inderes Modulightille 0,5 MEUR:n tilaus - Inderes Tilauksen toimitukset on suunniteltu ajoittuviksi vuoden 2025 toiselle puoliskolle ja vuoden 2026 ensimmäiselle puoliskolle.

yesterday

by Sijoittaja-alokas

5

Kiva uutinen Pikkaisen näyttäisi tosin, että vanha Pay-Per-Treatment -malli ei toimi, koska Modulight on halunnut asettaa minimihoitomääriä. Olenkin epäillyt tätä alusta alkaen, kun eihän ole mitään järkeä toimittaa laitteistoa asiakkaalle lojumaan, jos sitä käytetään vain kerran...

11/8/2024, 8:57 AM

by MoneyWalker

5

Näin itsekin ymmärrän tiedotteen. Hyvä asia, että minimikorvauksesta on sovittu ja osoittaa samalla asiakkaan aikomusta myös suorittaa hoitoja. Miten paljon lopun viimein synnyttää tulovirtaa minimi yli, jää nähtäväksi. Varmasti vuosi 2025 antaa hyvää käsitystä asiasta. Oletuksena...

11/8/2024, 1:37 PM

by Jopinaattori

3

Read more on our forum

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.